The Naurex Team
Management
|
Derek A. Small COO & Acting CEO |
President of Luson Bioventures which focuses on starting and launching
new biotech entities; is currently or has previously lead business and drug development as part of early or founding management at Semaphore
Pharmaceuticals, Simdesk, Kinagen, Coferon, and other start ups. |
|
|
Joseph R. Moskal, PhD Founder, President & Chief Scientist |
Director of the Falk Center for Molecular Therapeutics, Professor, Biomedical Engineering
, Northwestern University; previously Albert Einstein College of Medicine and National Institutes of Health. |
|
|
J. David Leander, PhD Chief Scientific Advisor |
Currently advised biopharma/ Previously 21+ years at Lilly. Lilly Research Fellow, chair of
Neuroscience Discovery groups that developed fluoxetine (Prozac), olanzapine (Zyprexa), atomoxetine (Strattera), duloxetine (Cymbalta), and many
others; >200 publications. |
|
|
Ronald M Burch, MD PhD Chief Medical Officer |
Chairman, Biowave Corp. Previously >20 years in various aspects of discovery research, drug development
and regulatory affairs, product assessment and planning. Previously founder and CEO, AlgoRx Pharmaceuticals, Cure Therapeutics; positions with
Pacira, Purdue Pharma, Zeneca, Rhone Poulenc-Rorer and Nova, National institutes of Health. |
|
|
Amin Khan, PhD Head of Chemistry |
Senior chemist with > 20 years experience in various biotechs including Elan, Gliatech and
others; discovered and developed multiple novel molecules to first-in-human studies. |
Clinical & Science Advisors
|
John F. Disterhof, PhD Learning and Memory |
Professor of Physiology, Director, Northwestern University Institute for Neuroscience,
Feinberg School of Medicine. |
|
|
Frank Menniti, PhD CNS Drug Discovery |
Recently retired Pfizer Research Fellow; lead discovery and development teams for several
CNS programs including NMDA receptor antagonists. |
|
|
George Miljanich, PhD CNS Drug Discovery & Development, Pain |
>20 years in drug development; with Elan, lead preclinical and clinical development for
the analgesic Prialt (N-type calcium channel inhibitor). |
|
|
Patric K. Stanton, PhD Preclinical models (electrophysiology) |
Professor of Cell Biology & Anatomy, New York College of Medicine. Early pioneer in the
development of LTD and LTP paradigms. |
|
|
David C. U'Prichard, PhD CNS Drug Discovery & Development |
President, Druid Consulting LLC and Partner, Red Abbey
Ventures. Previously, CEO of 3D Pharmaceuticals, Chair of R&D at SmithKline Beecham, Exec VP of R&D at Zeneca; oversaw development
of Seroquel®, Accolate®, Avandia®, and Iressa®. |
|
|
Paul L. Wood, PhD CNS Drug Development |
>20 years senior management experience in pharma and biotech. Preclinical development at
Ciba, Elan, CoCensys, GD Searle, Merck. Put first NMDA ligand into the clinic at Ciba; >200 publications. |
Board of Directors
|
Ed Chandler |
Founder and Managing Director of Portage Ventures, a Draper Fisher Jevetson fund. Mr.
Chandler currently serves on the boards of several early stage venture-backed companies. |
|
|
Bert Atwater Getz Jr. |
Director and Co-Chief Executive Officer of the Globe Corporation. Mr. Getz is also President
of Globe Development Corporation, an Officer and Director of Globe Management Company, and Chairman of the Investment Committee for Globe
Investment Company LP. |
|
|
Jan Edward Leetsma, MD Secretary |
Cofounder of Naurex. Former Dean of Students, University of Chicago, Division of the
Biological Sciences and the Prtizker School of Medicine. Dr. Leetsma is currently a private consultant practice in forensics and neuropathology. |
|
|
Joseph R. Moskal, PhD Executive Officer |
||
|
Derek A. Small Executive Officer |
||
|
J. Stark Thompson, PhD |
Recent past President, CEO and member of the board of directors of Life Science
Technologies, Inc. (NASDAQ:LTEK) and senior executive at DuPont. Dr. Thompson currently serves on the the boards of several biotechnology-focused
companies. |
|
|
David C. U'Prichard, PhD Member of Science & Clinical Advisory Board |